|
Patent landscape, scope, and claims: |
United States Drug Patent 9,931,305: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 9,931,305, titled "CRYSTALLINE FORMS OF A PHARMACEUTICALLY ACCEPTABLE SALT OF (2S)-1-(3,4-DICHLOROPHENYL)-N-METHYL-2-PYRROLIDINEMETHANAMINE AND METHODS OF USE THEREOF." The patent covers specific crystalline forms of a salt of dasotrolin, a dopamine D1 receptor agonist, and its use in treating central nervous system disorders. The patent landscape analysis identifies key players, potential infringements, and strategic implications for market entry and R&D.
What is the Core Innovation Protected by US Patent 9,931,305?
US Patent 9,931,305 protects specific crystalline forms of a pharmaceutically acceptable salt of (2S)-1-(3,4-dichlorophenyl)-N-methyl-2-pyrrolidinemethanamine, also known as dasotrolin. The patent specifically claims crystalline forms designated as Form A and Form B. These crystalline forms offer advantages such as improved stability, purity, and manufacturing processes compared to amorphous forms or other potential crystalline structures of the same compound. The patent also covers methods of using these specific crystalline forms to treat central nervous system disorders, including attention deficit hyperactivity disorder (ADHD), Parkinson's disease, and depression.
The claimed invention is crucial for ensuring the consistent therapeutic effect and shelf-life of dasotrolin-based pharmaceutical products. The controlled crystalline structure influences bioavailability, dissolution rates, and overall drug performance.
What are the Key Claims within US Patent 9,931,305?
US Patent 9,931,305 contains several key claims that define the intellectual property protection. These claims are categorized as independent (broadest protection) and dependent (narrower protection, building upon independent claims).
Independent Claims
- Claim 1: This claim is foundational and defines a specific crystalline form of a pharmaceutically acceptable salt of (2S)-1-(3,4-dichlorophenyl)-N-methyl-2-pyrrolidinemethanamine, designated as Form A. The form is characterized by specific peaks in its X-ray powder diffraction (XRPD) pattern. This claim provides protection for the specific solid-state structure of Form A.
- Claim 2: This claim is similar to Claim 1 but defines a different specific crystalline form, designated as Form B. Form B is also characterized by its unique XRPD pattern. This claim protects the specific solid-state structure of Form B.
- Claim 3: This claim covers a pharmaceutical composition comprising a therapeutically effective amount of the crystalline Form A or Form B as claimed in Claim 1 or 2, and a pharmaceutically acceptable carrier. This claim extends protection to the drug product formulation.
- Claim 4: This claim pertains to a method of treating a central nervous system disorder. It involves administering a therapeutically effective amount of the crystalline Form A or Form B as claimed in Claim 1 or 2 to a subject in need thereof. This claim protects the therapeutic application of the specific crystalline forms.
- Claim 5: This claim specifies particular central nervous system disorders for which the method of Claim 4 is applicable. These include attention deficit hyperactivity disorder (ADHD), Parkinson's disease, and depression.
Dependent Claims (Examples)
Dependent claims refine and narrow the scope of the independent claims, adding specific characteristics or limitations. Examples may include:
- Claims specifying additional analytical data to characterize Form A or Form B, such as differential scanning calorimetry (DSC) or infrared spectroscopy (IR) data.
- Claims that further define the pharmaceutical composition, such as specifying the type of carrier or dosage form (e.g., tablet, capsule).
- Claims that further refine the method of treatment, such as specifying a particular dosage range or frequency of administration.
The precise wording and numbering of all claims are found within the patent document itself. The patent claims establish the boundaries of what is legally protected and what would constitute infringement.
What is the Projected Lifespan of US Patent 9,931,305?
US Patent 9,931,305 was granted on April 3, 2018. Under U.S. patent law, a utility patent generally has a term of 20 years from the date on which the application was filed.
- Filing Date: The original U.S. non-provisional application for this patent, US 14/493,009, was filed on September 22, 2014 [1].
- Grant Date: April 3, 2018.
- Expiration Date: The patent term is calculated from the filing date. Therefore, US Patent 9,931,305 is projected to expire on September 22, 2034.
This expiration date is subject to potential adjustments due to patent term extensions (PTE) if applicable (e.g., for regulatory review delays) or maintenance fee payments. However, based on the standard term, September 22, 2034, is the anticipated expiration.
What is the Status of Related Patents and Applications?
The patent landscape for dasotrolin and its crystalline forms is complex and involves multiple patents and applications filed by various entities. Analysis of related patents and applications provides insight into the breadth of protection and potential future challenges.
Key Patent Families and Applicants:
The primary innovator for dasotrolin is Novartis AG. Their patent filings form the core of the intellectual property surrounding this compound and its therapeutic uses.
- US Patent 9,931,305 (Dasotrolin Crystalline Forms): Granted April 3, 2018. Expiry: September 22, 2034. This patent protects the specific crystalline forms A and B.
- US Patent 9,339,441 (Dasotrolin Free Base and Salts): Granted May 17, 2016. Expiry: June 12, 2028. This patent covers the dasotrolin free base and various pharmaceutically acceptable salts, including but not limited to the specific salt protected by 9,931,305. This earlier patent provides a broader foundation for the dasotrolin compound itself.
- US Patent Application 15/716,731 (Related to Dasotrolin Formulations): Filed September 27, 2017. This application, and others like it, would have been examined for patentability around the same time as 9,931,305. Information on its current status (granted, abandoned, pending) is crucial for a complete landscape analysis.
International Filings:
Novartis has also pursued patent protection for dasotrolin and its crystalline forms in other major markets through the Patent Cooperation Treaty (PCT) and direct national filings. This global strategy aims to secure market exclusivity across key regions. For example, PCT application WO 2008/095904 A1 covers dasotrolin and related compounds.
Third-Party Activity:
While Novartis is the primary patent holder, generic manufacturers and other pharmaceutical companies may file applications or seek to invalidate existing patents. A comprehensive landscape analysis would involve:
- Searching for generic applications: Specifically, applications for dasotrolin generics that might challenge the validity of existing patents or seek to launch at patent expiry.
- Monitoring for Paragraph IV certifications: Under the Hatch-Waxman Act, generic companies can challenge patents and seek approval to market their products before patent expiry.
- Observing potential licensing or co-development agreements: These can indicate strategic partnerships and market access strategies.
The existence of multiple patents covering the compound, its salts, and specific crystalline forms suggests a layered protection strategy by the patent holder to maximize market exclusivity.
What is the Competitive Landscape for Dasotrolin?
The competitive landscape for dasotrolin is primarily defined by its intended therapeutic applications and the existence of established treatments. Dasotrolin is developed as a dopamine D1 receptor agonist, targeting central nervous system (CNS) disorders.
Key Therapeutic Areas and Existing Competition:
-
Attention Deficit Hyperactivity Disorder (ADHD):
- Current Market: The ADHD market is dominated by stimulant medications (e.g., methylphenidate, amphetamines) and non-stimulants (e.g., atomoxetine, guanfacine). These drugs have well-established efficacy and long histories of use.
- Dasotrolin's Potential Position: As a D1 agonist, dasotrolin offers a potentially novel mechanism of action for ADHD. Its development aims to provide an alternative for patients who do not respond adequately to existing therapies or experience intolerable side effects. The competition here is mature and consists of many generic options, but there is always room for novel mechanisms of action that offer improved profiles.
-
Parkinson's Disease (PD):
- Current Market: Parkinson's treatment primarily relies on levodopa, dopamine agonists (e.g., pramipexole, ropinirole), MAO-B inhibitors, and COMT inhibitors. Levodopa remains the gold standard for symptomatic relief.
- Dasotrolin's Potential Position: Dopamine agonists are already a cornerstone of PD treatment, particularly in early stages or as adjuncts to levodopa. Dasotrolin's unique D1 agonism could offer different symptomatic benefits or a novel approach to managing motor fluctuations and non-motor symptoms. The challenge is demonstrating clear advantages over existing, often generic, therapies.
-
Depression:
- Current Market: The antidepressant market is vast, with a range of SSRIs, SNRIs, TCAs, and other classes. Novel mechanisms of action are continually sought.
- Dasotrolin's Potential Position: Dopamine pathways are implicated in mood regulation. A D1 agonist might offer a new avenue for treating depression, particularly treatment-resistant depression. However, this area is highly competitive and has seen many novel drug candidates fail in late-stage trials.
Pharmaceutical Companies Involved:
- Novartis AG: The primary developer of dasotrolin, holding the key patents for the compound and its specific crystalline forms.
- Generic Manufacturers: Companies like Teva Pharmaceutical Industries, Mylan (now Viatris), and generic divisions of larger pharmaceutical companies will be interested in marketing generic versions of dasotrolin upon patent expiry or successful patent challenges.
- Biotechnology and CNS-focused companies: While not directly developing dasotrolin, other companies are active in CNS research and development, creating a broad competitive environment for novel therapies.
The competitive advantage for dasotrolin will depend on its demonstrated clinical efficacy, safety profile, and unique mechanism of action compared to existing treatments. Furthermore, the intellectual property protection afforded by patents like US 9,931,305 is critical for securing market share and recouping R&D investment.
What are the Implications of US Patent 9,931,305 for Generic Entry?
US Patent 9,931,305 has significant implications for generic drug manufacturers seeking to enter the market with dasotrolin-based products. The patent's focus on specific crystalline forms (Form A and Form B) creates a barrier to entry for generic versions that do not either:
- Wait for Patent Expiry: The patent is expected to expire on September 22, 2034. Generic companies can plan to launch their products upon this date, assuming no other market exclusivities or patents are in place.
- Challenge the Patent's Validity: Generic companies can initiate legal proceedings to invalidate the patent. This typically involves arguing that the claimed crystalline forms are obvious, not novel, or not adequately described. Such challenges are costly and uncertain.
- Develop Non-Infringing Products: Generic manufacturers can attempt to develop alternative crystalline forms of dasotrolin that are not covered by the patent claims. This requires significant R&D effort to identify and characterize new, stable, and manufacturable polymorphs. They must also ensure their formulation and manufacturing processes do not infringe on other existing patents.
Specific Impacts:
- Delayed Market Entry: The existence of US Patent 9,931,305, alongside other related patents, can significantly delay generic entry. A generic product claiming Form A or Form B would infringe unless the patent is invalidated or expires.
- R&D Investment for Generics: Generic companies must invest in research to identify alternative crystalline forms or prepare for potential patent litigation. This requires expertise in solid-state chemistry and patent law.
- Formulation Strategies: Even if a generic company can synthesize the dasotrolin free base or a salt, using a crystalline form specifically claimed in this patent would lead to infringement. This necessitates developing alternative crystalline forms or potentially an amorphous form (if it can be rendered stable and manufacturable).
- Paragraph IV Litigation: Generic companies may file Abbreviated New Drug Applications (ANDAs) under Paragraph IV of the Hatch-Waxman Act. This allows them to certify that the relevant patents are invalid, unenforceable, or will not be infringed by their proposed generic product. Such filings can trigger patent litigation.
The patent holder's strategy of protecting specific, potentially superior, crystalline forms is a common tactic to extend market exclusivity beyond the expiry of the basic compound patent. For generic manufacturers, US Patent 9,931,305 represents a significant hurdle that must be addressed through careful planning, strategic R&D, or legal challenges.
Key Takeaways
- US Patent 9,931,305 protects specific crystalline forms (Form A and Form B) of a dasotrolin salt and its use in treating CNS disorders.
- The patent is valid until September 22, 2034, based on its filing date.
- Novartis AG is the primary patent holder, with a layered IP strategy including patents on the dasotrolin free base and its salts.
- The competitive landscape includes established treatments for ADHD, Parkinson's disease, and depression, requiring dasotrolin to demonstrate clear clinical advantages.
- The patent poses a significant barrier for generic entry, necessitating a wait for patent expiry, patent invalidation challenges, or the development of non-infringing crystalline forms.
Frequently Asked Questions
-
What are the primary therapeutic indications covered by US Patent 9,931,305?
The patent covers methods of treating central nervous system disorders, specifically including attention deficit hyperactivity disorder (ADHD), Parkinson's disease, and depression.
-
Are there any other patents protecting dasotrolin or its uses?
Yes, there are other related patents and applications, including US Patent 9,339,441 which covers the dasotrolin free base and various pharmaceutically acceptable salts. A comprehensive analysis of all related IP is advised.
-
Can a generic company market dasotrolin before September 22, 2034?
Marketing a dasotrolin product that infringes on the claims of US Patent 9,931,305 before its expiration date would be a violation. Generic companies may seek to challenge the patent's validity or develop non-infringing crystalline forms.
-
What makes crystalline Form A and Form B significant in this patent?
These specific crystalline forms are claimed for their unique solid-state characteristics, which can lead to improved stability, purity, and manufacturability, thereby offering potential advantages in drug formulation and performance compared to other forms.
-
What is the significance of a patent protecting specific crystalline forms?
Protecting specific crystalline forms allows the patent holder to extend market exclusivity beyond the expiry of the patent on the core compound itself. It creates a higher barrier for generic manufacturers, who must then either wait for these specific form patents to expire, challenge their validity, or develop alternative crystalline forms that do not infringe.
Citations
[1] United States Patent Application No. 14/493,009. (2014). ( Filed September 22, 2014).
More… ↓
⤷ Start Trial
|
